Lightwave Logic Inc (LWLG)

[ProfitScout]

OTCPicks.com Daily Market Movers Digest Midday Report for September 27th MCII, WRII, MANS, SIGA, TDON

Sep 27, 2007 (M2 PRESSWIRE via COMTEX) -- Our Stocks to Watch today include Mariner's Choice International (OTC: MCII), Waste Recovery Inc. (OTC: WRII), Manaris Corp. (OTCBB: MANS), Siga Technologies (NASD: SIGA), and Third Order Nanotech (OTC: TDON)

MARINER'S CHOICE INTERNATIONAL (OTC: MCII)

Detailed Quote: http://www.otcpicks.com/index.php?option=com_wrapper&Itemid=180

http://www.otcpicks.com/mariners-choice/mariners-choice.htm

Mariner's Choice is a global leader in providing eco-safe solutions through leading edge biodegradable technologies. Its primary focus is to provide high performance solutions across all marine industry sectors -- recreational and industrial -- without compromising performance. Mariner's Choice products reduce the cost of ownership, operations, and maintenance of marine assets. Each product is tested to exacting standards and performance levels of excellence, while providing the greatest benefit and satisfaction to the recreational and industrial customer. Mariner's Choice "green" products and nano-technology is a timely response to the environmental and health concerns that affect people globally. (www.marinerschoice.net)

MCII News:

September 26 - Mariner's Choice -- Forging Strong Partnerships is the Key to Success

Mariner's Choice International Inc. (OTC: MCII) aligns themselves with strategic partners to penetrate the marine market, and having an exclusive agency agreement with ComMar Sales, LLC, of Rhode Island is a case in point.

ComMar Sales was established in 1969 to service the marine industry as manufacturers' representative agency. Over the 38 years, they have proven their value time and time again through their dedication to sales, professionalism, and their strong work ethic. Currently, their team of 16 sales professionals covers the entire east coast, from New England to the Florida Keys.

"We are very excited to add Mariner's Choice line of products into our mix. Their performance-driven products are something we proudly present to our customer base, which ranges from OEMs, to marine distributors, to marina owners/operators, and retailers. The fact that all the products are eco-safe is a huge benefit, as the industry is facing more stringent regulations and hefty fines being handed down, not to mention the on-going concerns of the effects of harsh chemicals on the environment and people," states Norm MacLeod, Vice President of Sales at ComMar.

ComMar presents Mariner's Choice to their industrial/commercial accounts as a solutions provider to problems where caustic chemicals were traditionally being used. "The synergies between Mariner's Choice and ComMar are such that identifying opportunities seem virtually effortless. We have been participating in trade and dealer shows together, and have embarked on numerous sales promotion campaigns. Their strong rapport with key clients will serve Mariner's Choice well. We can only expect significant growth with a partnership like this," Peter Hellwig, Vice President of Mariner's Choice notes.

Recently, at the 2007 Marine Aftermarket Accessories Trade Show (MAATS) in Las Vegas, Norm MacLeod was named the President of National Marine Representatives Association (NMRA). His appointment is indicative of his dedication and commitment to the industry, as well as recognition of his professionalism and integrity.

WASTE RECOVERY INC (OTC: WRII) "Up 18.18% in morning trading"

Detailed Quote: http://finance.yahoo.com/q?s=WRII.PK

Waste Recovery, Inc. is a development stage corporation mandated by its shareholders to seek out business opportunities to acquire or merge with to create value for its shareholders.

WRII News:

September 27 - Waste Recovery, Inc. Announces the Retirement of 1.5 Billion Issued and Outstanding Shares

Robert R Susnar III, the newly appointed CEO of Waste Recovery, Inc. (OTC: WRII) announced the retirement of 1.5 Billion shares of stock.

"We are focused on getting our share price up and enhancing shareholder value," Susnar said in an interview today. "It is my belief that if we are in fact going to get this company on the right track we need to do everything in our power to make our shareholders money." According to Susnar this is the first step in many to come aimed at improving the cap structure of the company.

MANARIS CORP (OTCBB: MANS) "Up 5.88% in morning trading"

Detailed Quote: http://finance.yahoo.com/q?s=MANS.OB

Manaris operates two wholly-owned subsidiaries. Our Avensys subsidiary, through its manufacturing division Avensys Technologies, designs, manufactures, distributes, and markets high reliability optical components and modules as well as FBGs for the telecom market and high power devices and sub- assemblies for the industrial market. Avensys is also a pioneer in the development of packaged fiber-based sensors and possesses leading edge intellectual property. Avensys Solutions, is an industry leader in providing environmental monitoring solutions for air, water and soil, as well as geostructure in the Canadian. Our other subsidiary, C-Chip Technologies Corporation (North America) licensed its technology to its technology partner iMetrik Inc, whereby, C-Chip will receive royalties from iMetrik for its worldwide sales of GSM-based 'locate and disable' products into the 'Buy Here Pay Here' (BHPH) used car market.

MANS News:

September 27 - Manaris Corporation Reports All-Time Record Revenue for Fiscal Year 2007

Manaris Corporation (OTCBB: MANS; Frankfurt WKN: A0F5LD), a leading manufacturer and distributor of fiber optic components and integrator of instrumentation and turn-key systems for environmental monitoring, today reported its financial results for the fourth quarter and year ended June 30, 2007.

President and Chief Executive Officer John Fraser of Manaris Corp said, 'In the twelve months ended June 30, 2007, Manaris made further progress in sharpening our strategic focus. We improved the financial health of the Company as we nearly doubled our revenues. Our operating loss decreased significantly and our net working capital position was positive at year end. In our final quarter of the year ended June 30, 2007, we generated record quarterly revenue of $5.5 million.'

Subsequent to the fiscal year ended June 30, 2007, the Company focused on reducing the dilutive impact of past financings on its shareholders and establishing the platform for continued and sustainable growth. During the first quarter of fiscal 2008, Manaris redeemed the Series B Notes and Series B OID Notes ('Notes') issued in August 2006. The Company also redeemed a significant portion of the warrants attached to these Notes. In order to accomplish this redemption, on September 24, 2007, the Company entered into a Securities Purchase and Loan Agreement ('SPL Agreement') with Imperium for the sale of a 6% Original Issue Discount Senior Secured Convertible Note ('Convertible Note') in the amount of $4,708,900. The principal value and the gross proceeds of the Convertible Note is $4,000,000. The Convertible Note matures on September 24, 2012 and the original principal amount is convertible into common shares of the Company at a conversion price of $0.11 per share. The principal value will accrete to the value of the Convertible Note over a two year period and will subsequently accrue interest at 6%. Monthly installments of principal and interest will be payable commencing after the second year up to the maturity date.

The SPL Agreement also provides the holder of the Convertible Note with a Warrant to purchase up to 20,276,190 shares of the Company's outstanding common stock on a fully diluted basis. On August 22, 2007, the Company issued to the holder of the Convertible Note a Warrant to purchase up to 5% of the Company's outstanding common stock on a fully diluted basis. In addition, the SPL Agreement provides the Company with a $2,500,000 Working Capital Facility which will enable the Company to meet any immediate working capital requirements and fund future growth.

Mr. Fraser concluded, 'We continue to improve our manufacturing process and streamline costs. The positive results from Avensys confirm the validity of our strategic decision to use Avensys as a primary vehicle for future growth. Our objective is to continue to grow revenues and execute on the business strategy we have outlined.'

In conjunction with the earnings release, Manaris Corp will host a conference call with John Fraser, President and CEO, and Tony Giuliano, Chief Financial Officer. The call will take place, Thursday, September 27, 2007 at 11:00am ET and will be simultaneously broadcast live over the Internet at http://www.manariscorp.com or http://www.vcall.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. The online archive of the broadcast will be available within one hour of the live call.

SIGA TECHNOLOGIES (NASD: SIGA) "Up 15.51% in morning trading"

Detailed Quote: http://finance.yahoo.com/q?s=SIGA

SIGA is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junn, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA's product development programs also emphasize the increasingly serious problem of drug-resistant bacteria. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

SIGA News:

September 26 - ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates

SIGA Technologies, Inc. (NASDAQ: SIGA) today announced that its lead smallpox drug, ST-246, has passed another milestone by demonstrating 100% protection against death in cynomolgus monkeys showing signs of infection with monkeypox virus as part of a primate trial conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The study included a wide range of doses, all of which successfully prevented death, including a dose that was one one-hundredth of the dose given in prior primate trials. The amount of virus introduced into each animal is usually fatal absent ST-246 (all of the control subjects died), and all of the animals had developed fever and skin lesions prior to the administration of SIGA's drug.

"We are particularly pleased with the results of this study," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "The timing of drug administration in this study correlates to a late stage in the disease progression in humans. With this new information, we believe that ST-246 can be used to prevent mortality in humans even several days after elaboration of symptoms. Furthermore, the protection afforded by modest drug doses further enhances our confidence that a protective level in humans can be achieved with a low risk of toxicity," Hruby concluded.

In the study, once-daily, oral administration of ST-246 beginning 72 hours after infection protected cynomolgus monkeys from death following intravenous dosing with a lethal dose of monkeypox virus. ST-246 reduced lesion formation, reduced viral load and prevented death in all animals with no obvious toxicity. Furthermore, the test included a range of dosages (100 mg/kg to 3 mg/kg) of ST-246, and all were effective. The U.S. Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch, USAMRIID, funded and ran the study.

Commenting on the study, Dr. Huggins stated, "This is the first drug candidate that successfully treated monkeypox in our primate models after the onset of pox lesions, the most likely time that patients would be diagnosed with disease. We are encouraged and believe that this drug candidate may represent a practical solution to treating disease in a wider population where rapid laboratory-based diagnosis is not practical." Smallpox is considered one of the most significant biowarfare threats. The federal Centers for Disease Control and Prevention (CDC) classifies variola, the virus that causes smallpox, as a "Category A" (highest level threat) bioterrorism agent. Smallpox is readily transmitted between humans, it has significant mortality rates, and the population is no longer vaccinated against it. Mass immunizations of the general population using the current live vaccine can be problematic, as there are known complications affecting some individuals, which may include encephalitis, myocarditis, and death. Immunocompromised individuals receiving this vaccine are at particular risk from a systemic infection. At this time, there is also no approved treatment for smallpox.

The Department of Homeland Security has designated smallpox a "material threat" to our national security, which renders ST-246 eligible for purchase for the Strategic National Stockpile under Project Bioshield.

SIGA previously announced that ST-246 has been shown to be safe to administer to humans as a once-a-day pill. ST-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to ST-246.

THIRD ORDER NANOTECH (OTC: TDON) "Up 12.10% in morning trading"

Detailed Quote: http://finance.yahoo.com/q?s=TDON.PK

Third-Order Nanotechnologies is a development stage company, moving toward prototype demonstration and commercialization of its high-activity, high- stability organic polymers for applications in electro-optical device markets. Electro-optical devices convert data from electric signals into optical signals for use in high-speed communications systems and in optical interconnects for high-speed data transfer. Third-Order Nanotechnologies, Inc. is a portfolio company of Universal Capital Management, Inc. (OTC Bulletin Board: UCMT.OB). Please visit the Company's website, www.third-order.com for more information.

TDON News:

September 27 - Dan DiLeo, Formerly of Lucent and Agere, Joins Third-Order Nanotechnologies, Inc. Board of Advisors

Third-Order Nanotechnologies, Inc. (OTC: TDON) announced today that Dan DiLeo has joined its board of advisors.

'We believe that we have the opportunity to be the first major chipmaker of the photonic computing era. Dan brings a wealth of experience and insight from electronic chip making that could help us make this new paradigm a commercial reality,' commented Hal Bennett, CEO.

'This has the potential to be the silicon of the photonic computing paradigm. I think Third-Order Nanotechnologies has a fundamental technology that could form a platform to transform an entire industry,' commented Dan DiLeo.

Mr. DiLeo was Executive Vice President at Agere Systems and President and COO of Optoelectronics at Lucent Technologies - Microelectronics Group. In March 2001, he led an Agere Systems team through its investor presentations and IPO. Mr. DiLeo currently serves as director on the boards of several public and private companies in the US, and has an advisory role with a number of start-ups.

Mr. DiLeo holds several patents in semiconductor device design and processing. In addition to completing executive MBA programs at Tuck Graduate Business School of Dartmouth and INSEAD in Fontainebleau, France, DiLeo earned MSci and Tau Beta Pi BSci degrees in Materials and Metallurgical Engineering from Purdue University and Polytechnic Institute of NY, respectively.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [e-mail].

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated twenty thousand free trading shares by a third party (Delphina Group) for MCII advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2007 M2 COMMUNICATIONS LTD